Apremilast and adalimumab: A novel combination therapy for recalcitrant psoriasis

Dermatology Online Journal

Volumn 21, Issue 6, 2015, Pages

  Danesh, Melissa J ^a   Beroukhim, Kourosh ^b   Nguyen, Catherine ^c   Levin, Ethan ^a   Koo, John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biologic fatigue; Phosphodiesterase 4; TNF

Indexed keywords

ADALIMUMAB; APREMILAST; CLOBETASOL; ETANERCEPT; ETRETIN; STEROID; USTEKINUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; THALIDOMIDE;

ABDOMEN; ADD ON THERAPY; ADULT; ARM; BACK; CASE REPORT; CHRONIC INFLAMMATION; DISEASE DURATION; DRUG APPROVAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOPATHOLOGY; LEG; LETTER; MALE; PHOTOTHERAPY; PHYSICAL EXAMINATION; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RECURRENT DISEASE; REMISSION; THORAX; TREATMENT DURATION; TREATMENT OUTCOME; TRUNK; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; PSORIASIS; RETREATMENT;

ADALIMUMAB; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG THERAPY, COMBINATION; HUMANS; MALE; PSORIASIS; RETREATMENT; THALIDOMIDE;

EID: 84931024297     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (15)

1. Schafer, P.H., et al., Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cellular Signalling, 2014, 26(9): p. 2016-2029. PMID: 24882690
2. Gottlieb, A.B., et al., An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Current Medical Research and Opinion, 2008. 24(5): p. 1529-1538. PMID: 18419879
3. 3. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206088s000lbl.pdf.
4. Reich, K., et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase III, randomized, controlled trial (esteem 1). in JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2013. WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
5. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2). Journal of the American Academy of Dermatology, 2014. 70(5, Supplement 1): p. AB164. doi:10.1016/j.jaad.2014.01.682
6. Vergou, T., et al., Pharmacodynamics of TNF-alpha inhibitors in psoriasis. Expert Rev Clin Pharmacol, 2011. 4(4): p. 515-23. PMID: 22114860
7. Gottlieb, A.B., et al., Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: A phase II open-label study. Journal of Drugs in Dermatology, 2013. 12(8): p. 888-897. PMID: 23986162
8. Diani, M., G. Altomare, and E. Reali, T cell responses in psoriasis and psoriatic arthritis. Autoimmun Rev, 2014. PMID: 25445403
9. Gordon, K.B., et al., Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol, 2006. 55(4): p. 598-606. PMID: 17010738
10. Leonardi, C.L., et al., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet, 2008. 371(9625): p. 1665-74. PMID: 18486739
11. Papp, K.A., et al., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet, 2008. 371(9625): p. 1675-84. PMID: 18486740
12. Levin, E.C., et al., Biologic fatigue in psoriasis. J Dermatolog Treat, 2014. 25(1): p. 78-82. PMID: 23875537
13. Kavanaugh, A., et al., Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis. J Rheumatol, 2015. PMID: 25593233
14. Strand, V., et al., Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. Health Qual Life Outcomes, 11: p. 82. PMID: 23663752
15. Strand, V., et al., Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study. J Rheumatol, 2013. 40(7): p. 1158-65. PMID: 23588944